pages:
-
A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUS
-
A Phase I/II, Open-label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination with Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients with Advanced Cancer
-
A Phase I/II, open-label, multicentre, dose escalation study assessing the safety and tolerability of pEYS606 when administered by electrotransfer (ET) in the ciliary muscle of patients with non infectious posterior, intermediate or panuveitis.
Research Grant
-
A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors
-
A PHASE Ib DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATIONWITH ATEZOLIZUMAB, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LU
-
A Phase IB Dose-Escalation Study of TRC105 in combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma
-
A PHASE Ib STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH ADVANCED BRAFV600 WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI¿PD-1 THERAPY
Research Grant
-
A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or GIST.
-
A phase Ib, multi-arm, open-label, study of HDM201 in
combination with MBG453 or venetoclax in adult subjects
with acute myeloid leukemia (AML) or high-risk
myelodysplastic syndrome (MDS)
-
A PHASE Ib, MULTICENTER, OPEN-LABELSTUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN
PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABL
-
A Phase Ib, Open-Label, Two-Arm Study Evaluating The Safety And Pharmacokinetics Of Atezolizumab (ANTI-PD-L1 Antibody) In Combination With Trastuzumab Emtansine Or With Trastuzumab And Pertuzumab In Subjects With HER2 Positive Breast Cancer
-
A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
Research Grant
-
A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
-
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melan
-
A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML
-
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
-
A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON¿MUSCLEINVASIVE BLADDER CANCER
-
A Phase II , Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)
-
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Taxane in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial)
-
A Phase II multi-center, randomized, double-blind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy and safety of RO5285119 in children and adolescents age 5-17 with Autism Spectrum Disorder (ASD)
Research Grant
-
A Phase II of Entospletinib, a SYK Inhibitor, First line cGVHD patients
-
A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer
-
A phase II pilot trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma.
-
A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrom
-
A Phase II Randomized Double-blind Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS-181-2-05)
-
A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer
Research Grant
-
A PHASE II RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF LETROZOLE WITH OR WITHOUT BYL719 OR BUPARLISIB, FOR THE NEOADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER
-
A Phase II Randomized, Double-Blind Study ...
Fellowships, Supported Research, and Other Grants
-
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Finding, Safety and Efficacy Study of IDEC-114 ...
Fellowships, Supported Research, and Other Grants
-
A Phase II Randomized, Open-label, Multi-center Study of the Safety and
Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201
Positive Patients with Previously Untreated Advanced Uveal Melanoma
pages: